AU2012343536B2 - Immunogenic treatment of cancer - Google Patents

Immunogenic treatment of cancer Download PDF

Info

Publication number
AU2012343536B2
AU2012343536B2 AU2012343536A AU2012343536A AU2012343536B2 AU 2012343536 B2 AU2012343536 B2 AU 2012343536B2 AU 2012343536 A AU2012343536 A AU 2012343536A AU 2012343536 A AU2012343536 A AU 2012343536A AU 2012343536 B2 AU2012343536 B2 AU 2012343536B2
Authority
AU
Australia
Prior art keywords
cancer
tumour
immunomodulator
therapy
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012343536A
Other languages
English (en)
Other versions
AU2012343536A1 (en
Inventor
Charles AKLE
John Grange
Satvinder MUDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immodulon Therapeutics Ltd
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Publication of AU2012343536A1 publication Critical patent/AU2012343536A1/en
Application granted granted Critical
Publication of AU2012343536B2 publication Critical patent/AU2012343536B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012343536A 2011-12-02 2012-12-03 Immunogenic treatment of cancer Active AU2012343536B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1120779.2 2011-12-02
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (2)

Publication Number Publication Date
AU2012343536A1 AU2012343536A1 (en) 2014-06-05
AU2012343536B2 true AU2012343536B2 (en) 2017-08-24

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012343536A Active AU2012343536B2 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Country Status (15)

Country Link
US (4) US20140356397A1 (enExample)
EP (1) EP2785361B1 (enExample)
JP (1) JP6085611B2 (enExample)
KR (1) KR20140097419A (enExample)
CN (1) CN104023733A (enExample)
AU (1) AU2012343536B2 (enExample)
BR (1) BR112014012880A2 (enExample)
CA (1) CA2857429A1 (enExample)
GB (1) GB201120779D0 (enExample)
IL (1) IL232890A0 (enExample)
IN (1) IN2014MN00955A (enExample)
MX (1) MX2014006511A (enExample)
RU (1) RU2014121335A (enExample)
SG (1) SG11201402396XA (enExample)
WO (1) WO2013079980A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
WO2015102680A2 (en) 2013-09-11 2015-07-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for beam intensity-modulation to facilitate rapid radiation therapies
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA2975123A1 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
WO2016207646A1 (en) * 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
RU2018136347A (ru) * 2016-04-14 2020-05-14 Фелдрайх Каро Руиз Аб Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света
EP3600551A1 (en) 2017-03-28 2020-02-05 Emblation Limited Stenosis treatment
US11173325B2 (en) * 2017-07-21 2021-11-16 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agent
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
KR20210099073A (ko) 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
TW202138005A (zh) * 2019-12-27 2021-10-16 特定非營利活動法人北東日本研究機構 癌症治療方法及醫藥
WO2022101619A1 (en) 2020-11-10 2022-05-19 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
WO2023007107A1 (en) * 2021-07-27 2023-02-02 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008488A1 (en) * 1990-11-08 1992-05-29 University College London Mycobacterium as adjuvant for antigens
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
CA2369542C (en) 1999-04-23 2009-10-27 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
AU2006306521B2 (en) 2005-10-21 2011-12-22 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by TLR ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
US8557257B2 (en) * 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
US9114158B2 (en) * 2011-03-09 2015-08-25 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
WO2016207646A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
WO2020002905A1 (en) 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HROUDA et al. "Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer", BJU International, 2000, Vol. 86, Pages 742-748. *
O’BRIEN et al., British Journal of Cancer, 2000, Vol. 83, No. 7, Pages 853–857. *
STEBBING et al. "An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma", Annals of Oncology, 2012, Vol. 23, Pages 1314–1319. *
SUR PRABIR KUMAR ET AL., JOURNAL OF THE INDIAN MEDICAL ASSOCIATION, INDIAN MEDICAL ASSOCIATION, CALCUTTA, IN, (20030101), vol. 101, no. 2, ISSN 0019-5847, page 118,120. *
Yuk et al. "Bacillus Calmette-Guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy", Autophagy, 2010, Vol. 6, No. 1, Pages 46-60. *

Also Published As

Publication number Publication date
EP2785361A1 (en) 2014-10-08
CN104023733A (zh) 2014-09-03
US20230149525A1 (en) 2023-05-18
AU2012343536A1 (en) 2014-06-05
KR20140097419A (ko) 2014-08-06
MX2014006511A (es) 2014-12-05
US11318193B2 (en) 2022-05-03
BR112014012880A2 (pt) 2017-06-13
EP2785361B1 (en) 2018-11-28
NZ624994A (en) 2016-10-28
US20140356397A1 (en) 2014-12-04
JP6085611B2 (ja) 2017-02-22
IL232890A0 (en) 2014-07-31
CA2857429A1 (en) 2013-06-06
JP2014533743A (ja) 2014-12-15
US20190224294A1 (en) 2019-07-25
US11554166B2 (en) 2023-01-17
RU2014121335A (ru) 2016-01-27
GB201120779D0 (en) 2012-01-11
SG11201402396XA (en) 2014-10-30
IN2014MN00955A (enExample) 2015-04-24
US20200338181A1 (en) 2020-10-29
WO2013079980A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
US20230149525A1 (en) Immunogenic treatment of cancer
Breton et al. Microsecond and nanosecond electric pulses in cancer treatments
JP2025185047A (ja) がんの免疫学的処置
US9526911B1 (en) Immune mediated cancer cell destruction, systems and methods
Impellizeri et al. Electroporation in veterinary oncology
CN103800896A (zh) 一种自体肿瘤疫苗的制备方法及其应用
Séguier et al. Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer
JP2024506914A5 (enExample)
Tranberg Local destruction of tumors and systemic immune effects
Alshaibi et al. Modulated electrohyperthermia: A new hope for cancer patients
Rampersaud et al. Hyperthermia as a treatment for bladder cancer
Yang et al. Status and prospects of glioblastoma multiforme treatments
Guo et al. Role of endoscopic ultrasound in treatment of pancreatic cancer
WO2003049751A1 (en) The process of manufacturing a pharmaceutical composition useful for management of cancer
Lou et al. Multimodal thermal therapy for solid tumor: a new interventional immunomodulatory therapy
Zhang et al. Inhibitory and immunological effects induced by the combination of photodynamic therapy and dendritic cells on mouse transplanted hepatoma
NZ624994B2 (en) Immunogenic treatment of cancer
CN104083205A (zh) 一种肿瘤治疗系统和方法
Sugihara et al. Metronomic Photodynamic Therapy With Immune Checkpoint Inhibitors Does Not Affect Nontarget Lesions
RU2530523C2 (ru) Способ противоопухолевой иммунотерапии
Li et al. Laser immunotherapy: Concept, possible mechanism, clinical applications, and recent experimental results
US20210154296A1 (en) Vaccine or immunotherapeutic agent composition containing photothermally treated cell lysates as active ingredients
Testoni et al. Present and Future of Local Therapies for Unresectable Pancreatic Cancer
Nuccitelli Nanosecond Pulsed Field Ablation in Oncology. Medical Research Archives,[online] 13 (8)
TR2025006375A2 (tr) Büyük hücreli, baş ve boyun kanseri için mrna aşısı

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)